StockData

Absci vs OneMedNet

ABSI and ONMD side by side, both in engineering, accounting, research, management, and related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABSI and ONMD compare

Absci is the larger company, worth 4.6 times as much as OneMedNet ($1.5B against $317M).

OneMedNet grew revenue faster over the last twelve months (217% versus −47.2% for Absci).

OneMedNet keeps more of each dollar of sales as profit, with a net margin of −584% compared with −8451% at Absci.

Absci scores higher on the StockData Score (5 against 3 for OneMedNet), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABSIONMD
Size and price
Market cap$1.5B$317M
Share price$8.45$5.34
Change, 1 year149%−64.6%
Change, 5 years−23.5%−94.7%
Beta (5Y)2.19−0.24
Employees14023
StockData Score
Total score5 (better)3
Valuation score00
Growth score02 (better)
Performance score01 (better)
Health score5 (better)0
Dividend score00
Valuation
P/S975×217× (better)
P/B6.6×–
FCF yield−7.8%−2.2% (better)
Growth
Revenue growth (TTM)−47.2%217% (better)
Revenue growth, 5Y average−10.1%–
Profitability
Gross margin–−68.8%
Operating margin−8812%−696% (better)
Net margin−8451%−584% (better)
FCF margin−7563%−473% (better)
Return on equity−58.6%–
Return on invested capital−242%–
Financial health
Debt / equity0.00–
Interest coverage−2569.4×−307.0× (better)
Current ratio9.64 (better)0.28
Altman Z-score36.44 (better)−99.41
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield−7.6%–
Shareholder yield−7.6%0.00% (better)
Ownership
Held by institutions88.3%10.2%
Held by insiders15.5%6.9%
Insider net buying, 12 months$801K$4.1M (better)
Short interest, % of float24.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.